LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

Search

Arcus Biosciences Inc

Suletud

SektorTervishoid

9.36 2.86

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.72

Max

9.47

Põhinäitajad

By Trading Economics

Sissetulek

-18M

-112M

Müük

2M

28M

Aktsiakasum

-1.14

Kasumimarginaal

-400

Töötajad

627

EBITDA

-34M

-122M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+170.48% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

90M

1.1B

Eelmine avamishind

6.5

Eelmine sulgemishind

9.36

Uudiste sentiment

By Acuity

63%

37%

340 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

Arcus Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. juuni 2025, 20:41 UTC

Tulu

Adobe Raises Outlook After 2Q Sales Beat

12. juuni 2025, 23:50 UTC

Tulu

Adobe Keeps Pivoting as AI Transforms Customer Needs -- Update

12. juuni 2025, 23:50 UTC

Tulu

Adobe Customer Demand Shifting Toward Idea Generation, CFO Says

12. juuni 2025, 23:50 UTC

Tulu

Adobe FireFly Products Drove Revenue Beat in 2Q, CFO Says

12. juuni 2025, 23:48 UTC

Market Talk

Gold Steady Amid Geopolitical Risks -- Market Talk

12. juuni 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. juuni 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

12. juuni 2025, 21:26 UTC

Tulu

Friedman Industries 4Q Sales $129.2M >FRD

12. juuni 2025, 21:25 UTC

Tulu

Friedman Industries 4Q EPS 76c >FRD

12. juuni 2025, 21:11 UTC

Tulu

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12. juuni 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

12. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. juuni 2025, 20:31 UTC

Tulu

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12. juuni 2025, 20:30 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Chime IPO: Stock Soars in Nasdaq Debut, Valuing It at Nearly $14 Billion -- Barrons.com

12. juuni 2025, 20:15 UTC

Tulu

Adobe Sees FY25 Rev $23.5B-$23.6B >ADBE

12. juuni 2025, 20:15 UTC

Tulu

Adobe Sees 3Q Rev $5.88B-$5.93B >ADBE

12. juuni 2025, 20:14 UTC

Tulu

Adobe Stock Pops as Earnings Beat Estimates -- Barrons.com

12. juuni 2025, 20:07 UTC

Tulu

Adobe Raises FY25 Rev and EPS Targets

12. juuni 2025, 20:05 UTC

Tulu

Adobe Sees FY Adj EPS $20.50-Adj EPS $20.70 >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe 2Q Digital Experience Revenue $1.46B >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe 2Q Digital Media Revenue $4.35B >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe Sees 3Q EPS $4.00-EPS $4.05 >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe 2Q Net $1.69B >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe 2Q EPS $3.94 >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe 2Q Digital Experience Revenue Up 10% >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe 2Q Rev $5.87B >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe Sees 3Q Adj EPS $5.15-Adj EPS $5.20 >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe Sees FY EPS $16.30-EPS $16.50 >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe 2Q Digital Media Revenue Up 11% >ADBE

12. juuni 2025, 20:05 UTC

Tulu

Adobe 2Q Adj EPS $5.06 >ADBE

Võrdlus sarnastega

Hinnamuutus

Arcus Biosciences Inc Prognoos

Hinnasiht

By TipRanks

170.48% tõus

12 kuu keskmine prognoos

Keskmine 25.29 USD  170.48%

Kõrge 46 USD

Madal 12 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Arcus Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

8

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

8.01 / 8.75Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

340 / 380 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.